Germline mutations of the tumour suppressor gene BRCA1 are involved in the predisposition and development of breast cancer and account for 20 -45% of all hereditary cases. There is an increasing evidence that these tumours are characterised by a specific phenotype and pattern of gene expression. We have hypothesised that differences in chemosensitivity might parallel molecular heterogeneity of hereditary and sporadic breast tumours. To this end, we have investigated the chemosensitivity of the BRCA1-defective HCC1937 breast cancer cell line, and the BRCA1-competent MCF-7 (hormone-sensitive) and MDA-MB231 (hormoneinsensitive) breast cancer cell lines using the MTT assay. The 50% inhibitory concentration (IC 50 ) for the individual compounds were derived by interpolate plot analysis of the logarithmic scalar concentration curve after a 48 h exposure. HCC1937 cells were significantly (Po0.005) more sensitive to cisplatin (CDDP) (IC 50 : 30-40 mM) compared with MCF-7 (IC 50 : 60-70 mM) and MDA-MB231 (IC 50 : 90 -100 mM) cells. On the other hand, BRCA1-defective breast cancer cells were significantly less sensitive to doxorubicin (Dox) (IC 50 : 45-50 mM) compared with MCF-7 (IC 50 : 1-5 mM) and MDA-MB231 (IC 50 : 5-10 mM) (Po0.02), as well as to paclitaxel (Tax) (IC 50 : 42 mM for HCC1937, 0.1 -0.2 mM for MCF-7 and 0.01 -0.02 mM for MDA-MB231) (Po0.001). Full-length BRCA1 cDNA transfection of BRCA1-defective HCC1937 cells led to the reconstituted expression of BRCA1 protein in HCC1937/ WT BRCA1-derived cell clone, but did not reduce tumour cell growth in soft agar. BRCA1 reconstitution reverted the hypersensitivity to CDDP (Po0.02), and restored the sensitivity to Dox (Po0.05) and Tax (Po0.001), compared with parental HCC1937 cells. Taken together, our findings suggest a specific chemosensitivity profile of BRCA1-defective cells in vitro, which is dependent on BRCA1 protein expression, and suggest prospective preclinical and clinical investigation for the development of tailored therapeutical approaches in this setting.
Metastatic breast cancer cells disseminate to organs with a soft
microenvironment. Whether and how local tissue mechanical properties influence
their response to treatment remains unclear. Here we found that a soft ECM
empowers redox homeostasis. Cells cultured on a soft ECM display increased
peri-mitochondrial F-actin promoted by Spire1C and Arp2/3 nucleation factors,
and increased DRP1- and MIEF1/2-dependent mitochondrial fission. Changes in
mitochondrial dynamics lead to increased mtROS production and activate the NRF2
antioxidant transcriptional response, including increased cystine uptake and
glutathione metabolism. This retrograde response endows cells with resistance to
oxidative stress and ROS-dependent chemotherapy drugs. This is relevant in a
mouse model of metastatic breast cancer cells dormant in the lung soft tissue,
where inhibition of DRP1 and NRF2 restored cisplatin sensitivity and prevented
disseminated cancer cell awakening. We propose that targeting this mitochondrial
dynamics- and redox-based mechanotransduction pathway could open avenues to
prevent metastatic relapse.
Immune-checkpoint blockade by Nivolumab, a human monoclonal antibody to programmed cell death receptor-1, is an emerging treatment for metastatic non-small cell lung cancer (mNSCLC). In order to prolong patient survival, this treatment requires a continuous cross-priming of tumor derived-antigens to supply fresh tumor-specific immune-effectors; a phenomenon that may also trigger auto-immune-related adverse events (irAEs). The present study therefore investigated the prognostic value of multiple autoimmunity-associated parameters in patients with mNSCLC who were undergoing Nivolumab treatment. This retrospective study included 92 mNSCLC patients who received salvage therapy with Nivolumab (3 mg/kg, biweekly) between September 2015 and June 2018. Log-rank test, Mantel-Cox and McPherson analyses were conducted to correlate patient progression-free survival (PFS) and overall survival (OS) with different parameters including blood cell counts, serum inflammatory markers and auto-antibodies (AAbs). A median PFS and OS of 10 [inter-quartile range (IQR): 5.8-14.2] and 16 [IQR: 6.2-25.8] months, respectively, were recorded, which did not correlated with age, histology or the number of previous chemotherapy lines. Male gender, the type of therapeutic regimens received prior to Nivolumab, and the occurrence of irAEs were revealed to be positive predictors of prolonged survival (P<0.05). Early detection (within 30 days) of >1AAbs among anti-nuclear antigens (ANAs), extractable nuclear antigens (ENAs) and anti-smooth cell antigens (ASMAs) correlated with prolonged PFS [hazard ratio (HR)= 0.23; 95% confidence interval (
The interleukin-2 is a cytokine that is essential for lymphocytic survival and function. Ectopic expression of the IL-2 receptor in epithelial tissues has been reported previously, although the functional significance of this expression is still being investigated. We provided novel structural and functional information on the expression of the IL-2 receptor in kidney cancer cells and in other normal and neoplastic human epithelial tissues. In A-498 kidney cancer cells, we showed that IL-2 binding to its own receptor triggers a signal transduction pathway leading to the inhibition of proliferation and apoptosis. We found that the inhibition of proliferation is associated with Erk1/2 dephosphorylation, whereas the survival signals appear to be mediated by Sgk1 activation. This investigation focuses on the IL-2 induced regulation of Sgk1 and describes a role of the IL-2 receptor and Sgk1 in the regulation of epithelial tumor cell death and survival.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.